Drug intelligence / Profile preview

MR-201

Development stage: Preclinical
Lead developer: SHINKEI Therapeutics
Modality: Small Molecules

Overview

MR-201 is a novel dosage form developed by SHINKEI Therapeutics for the treatment of Pseudobulbar Affect (PBA). It acts as an NMDA receptor antagonist. The drug is in the early stages of clinical development, with an Investigational New Drug (IND) application submitted to the FDA. The primary goal is to leverage existing data to accelerate its approval via the 505(b)(2) pathway.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on MR-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR-201.

Explore the full profile